The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

References

• Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143–3421.
   Google Scholar
• Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England Journal of Medicine 2001; 345: 1583–1592
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 2005; 258: 94–114
   Google Scholar
• Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends in Pharmacological Sciences 2006; 27: 384–390
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: From promise to practice. Netherlands Journal of Medicine 2004; 62: 229–234
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Morgan JM, Brusco OA, Jr, Intenzo CM. Niacin dosing: Relationship to benefits and adverse effects. Current Atherosclerosis Reports 2000; 2: 64–71
   PubMedGoogle Scholar
• Mills E, Prousky J, Raskin G, Gagnier J, Rachlis B, Montori VM, Juurlink D. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clinical Pharmacology 2003; 3
   Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. American Journal of Cardiology 1998; 82: 29U–34U
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Molecular Pharmacology 2006; 70: 1844–1849
   PubMed Web of Science ®Google Scholar
• Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences of USA 2006; 103: 6682–6687
   PubMed Web of Science ®Google Scholar
• Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. Journal of Investigative Dermatology 2006; 126: 2637–2646
   PubMed Web of Science ®Google Scholar
• Morrow JD, Parsons WG, III, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989; 38: 263–274
   PubMedGoogle Scholar
• Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. Journal of Investigative Dermatology 1992; 98: 812–815
   PubMed Web of Science ®Google Scholar
• Phillips WS, Lightman SL. Is cutaneous flushing prostaglandin mediated?. Lancet 1981; 1: 754–756
   PubMed Web of Science ®Google Scholar
• Wilkin JK, Fortner G, Reinhardt LA, Flowers OV, Kilpatrick SJ, Streeter WC. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clinical Pharmacology & Therapeutics 1985; 38: 273–277
   PubMed Web of Science ®Google Scholar
• Chang SW, Reddy V, Pereira T, Dean BJ, Xia YQ, Seto C, Franklin RB, Karanam BV. The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 2007; 37: 514–533
   PubMed Web of Science ®Google Scholar
• Lai E, De Lepeleire I, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, O’Neill, Wagner JA, Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1. Clinical Pharmacology & Therapeutics 2007; 81: 849–857
   PubMed Web of Science ®Google Scholar
• Levesque JF, Day SH, Chauret N, Seto C, Trimble L, Bateman KP, Silva JM, Berthelette C, Lachance N, Boyd M, et al. Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: Impacts of glutathione trapping and glucuronide conjugation on covalent binding. Bioorganic & Medicinal Chemistry Letters 2007; 17: 3038–3043
   PubMed Web of Science ®Google Scholar
• Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). Journal of Medicinal Chemistry 2007; 50: 794–806
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. American Journal of Cardiology 2008; 101: 625–630
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin as an antiplatelet drug. The New England Journal of Medicine 1994; 330: 1287–1294
   PubMed Web of Science ®Google Scholar
• Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends in Pharmacological Sciences 1991; 12: 158–163
   PubMed Web of Science ®Google Scholar
• Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, et al. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010; 21: 191–198
   PubMed Web of Science ®Google Scholar
• Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: A review of its mechanism of action. Platelets 1998; 9: 251–255
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England Journal of Medicine 2010; 363: 930–942
   PubMed Web of Science ®Google Scholar
• Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. The New England Journal of Medicine 1972; 287: 155–159
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thrombosis, and Vascular Biology 2004; 24: 1980–1987
   PubMed Web of Science ®Google Scholar
• Mangin P, Ohlmann P, Eckly A, Cazenave JP, Lanza F, Gachet C. The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. Journal of Thrombosis and Haemostasis 2004; 2: 969–977
   PubMed Web of Science ®Google Scholar